Abstract
Purpose
To investigate the prevalence and clinical aspects of Sjögren syndrome in patients who were diagnosed with dry eye syndrome in Korea.
Methods
The medical records of patients who were diagnosed with dry eye syndrome in a dry eye clinic during a 2-year period (March 2008 to March 2010) and were followed up for more than 3 months were reviewed retrospectively.
Results
A total of 206 patients were included in the present study. Fifty-eight patients (28%) had Sjögren syndrome and 39 patients (19%) showed primary Sjögren syndrome. Sjögren syndrome patients showed poorer results than non-Sjögren syndrome patients in ocular surface disease index score (OSDI), tear break up time, Schirmer test score, and ocular surface staining score using the Oxford scheme (p < 0.05). Among the patients with primary Sjögren syndrome, 27 patients were SSA (anti-Ro antibodies) or SSB (anti-La antibodies) positive and 12 patients were sero-negative. There were no statistically significant differences in objective or subjective parameters between the sero-positive and sero-negative groups.
Conclusions
Sjögren syndrome was observed in 28% of all dry eye patients, in two-thirds of severe dry eye patients. Sjögren syndrome patients showed more severe clinical aspects than dry eye patients with non-Sjögren syndrome. Diagnosing Sjögren syndrome through systemic evaluation is necessary in the patients with severe dry eye.
Figures and Tables
References
1. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007. 5:75–92.
2. Chung SH, Na KS, Kwon HG, et al. Levels of severity in dry eye syndrome according to Delphi panel classification. J Korean Ophthalmol Soc. 2010. 51:1179–1183.
3. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000. 118:1264–1268.
4. Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol. 2004. 122:369–373.
5. Djalilian AR, Hamrah P, Pflugfelder SC. Krachmer JH, Mannis MJ, Holland EJ, editors. Dry eye. Cornea. 2005. 2nd ed. St. Louis, MO: Elsevier Mosby;521–540.
6. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999. 19:201–211.
7. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001. 42:2283–2292.
8. Bron AJ, Evans VE, Smith JA, et al. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003. 22:640–650.
9. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000. 118:615–621.
10. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002. 61:554–558.
11. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol. 1998. 37:1069–1076.
12. Jacobsson LT, Axell TE, Hansen BU, et al. Dry eyes or mouth--an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome. J Autoimmun. 1989. 2:521–527.
13. Bjerrum KB. Keratoconjunctivitis sicca and primary Sjögren's syndrome in a Danish population aged 30-60 years. Acta Ophthalmol Scand. 1997. 75:281–286.
14. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol. 2000. 29:341–348.
15. Alexander EL, Arnett FC, Provost TT, Stevens MB. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med. 1983. 98:155–159.
16. Akpek EK, Klimava A, Thorne JE, et al. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea. 2009. 28:493–497.
17. Goto E, Matsumoto Y, Kamoi M, et al. Tear evaporation rates in Sjögren syndrome and non-Sjögren dry eye patients. Am J Ophthalmol. 2007. 144:81–85.
18. Horwath-Winter J, Berghold A, Schmut O, et al. Evaluation of the clinical course of dry eye syndrome. Arch Ophthalmol. 2003. 121:1364–1368.
19. Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjögren syndrome. Cornea. 2007. 26:S13–S15.
20. Tuisku IS, Konttinen YT, Konttinen LM, Tervo TM. Alterations in corneal sensitivity and nerve morphology in patients with primary Sjögren's syndrome. Exp Eye Res. 2008. 86:879–885.
21. Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. Am J Ophthalmol. 2010. 149:405–415.
22. Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2006. 20:791–807.
23. Dawson LJ, Caulfield VL, Stanbury JB, et al. Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005. 44:449–455.